Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 983-990

  Slagman, Maartje C J ^a   Waanders, Femke ^a   Vogt, Liffert ^a,b   Damman, Kevin ^a   Hemmelder, Marc ^c   Navis, Gerjan ^a   Laverman, Gozewijn D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Dietary sodium restriction; Diuretics; Hypertension; N terminal pro brain natriuretic peptide; Proteinuria

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION; TREATMENT OUTCOME;

EID: 84861108594     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr408     Document Type: Article

References (38)

1. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
2. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
3. Kidney Disease Outcomes Quality Intiative. Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290
4. Thomas MC. The assessment and management of albuminuria in primary care. Diabetes Res Clin Pract 2008; 80: 83-88
5. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48
6. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762
7. De Nicola L, Minutolo R, Bellizzi V et al. Achievement of target blood pressure levels in chronic kidney disease: a salty question? Am J Kidney Dis 2004; 43: 782-795
8. Ritz E, Dikow R, Morath C et al. Salt-a potential'uremic toxin'? Blood Purif 2006; 24: 63-66
9. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 2003; 64: 1772-1779
10. Navis G, de Jong P, Donker AJ et al. Diuretic effects of angiotensinconverting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987; 9: 743-748
11. Buter H, Hemmelder MH, Navis G et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685
12. Houlihan CA, Allen TJ, Baxter AL et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25: 663-671
13. Ekinci EI, Thomas G, Thomas D et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care 2009; 32: 1398-1403
14. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007
15. Esnault VL, Ekhlas A, Delcroix C et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16: 474-481
16. Slagman MC, Waanders F, Hemmelder MH et al. Moderate dietary sodium restriction added to ACE inhibition is more effective than dual blockade in lowering blood pressure and proteinuria: results from a randomised controlled trial. BMJ 2011
17. Esnault VL, Ekhlas A, Nguyen JM et al. Diuretic uptitration with half dose combined ACEI 1 ARB better decreases proteinuria than combined ACEI 1 ARB uptitration. Nephrol Dial Transplant 2010; 25: 2218-2224
18. Obarzanek E, Proschan MA, Vollmer WM et al. Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension 2003; 42: 459-467
19. Weir MR, Dengel DR, Behrens MT et al. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25: 1339-1344
20. Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71: 260-265
21. Bellizzi V, Scalfi L, Terracciano V et al. Early changes in bioelectrical estimates of body composition in chronic kidney disease. J Am Soc Nephrol 2006; 17: 1481-1487
22. Weir MR, Dworkin LD. Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy? Am J Kidney Dis 1998; 32: 1-22
23. Hamming I, Navis G, Kocks MJ et al. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209: 129-139
24. Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191-2201
25. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130
26. Murdoch DR, McDonagh TA, Byrne J et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138: 1126-1132
27. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004; 90: 765-770
28. Collinson PO, Barnes SC, Gaze DC et al. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004; 6: 365-368
29. Locatelli F, Eckardt KU, Macdougall IC et al. Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study. Curr Med Res Opin 2010; 26: 2543-2552
30. Takami Y, Horio T, Iwashima Y et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44: 420-428
31. Wang AY, Lam CW, Yu CM et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007; 18: 321-330
32. Oterdoom LH, de Vries AP, van Ree RM et al. N-terminal pro-B-type natriuretic peptide and mortality in renal transplant recipients versus the general population. Transplantation 2009; 87: 1562-1570
33. de Lemos JA, Hildebrandt P. Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol 2008; 101: 16-20
34. Wang TJ, Larson MG, Levy D et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663
35. Melander O, von Wowern F, Frandsen E et al. Moderate salt restriction effectively lowers blood pressure and degree of salt sensitivity is related to baseline concentration of renin and N-terminal atrial natriuretic peptide in plasma. J Hypertens 2007; 25: 619-627
36. Van Zuilen AD, Wetzels JF, Bots ML et al. MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol 2008; 21: 261-267
37. De Nicola L, Minutolo R, Chiodini P et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 2006; 69: 538-545
38. Brown IJ, Tzoulaki I, Candeias V et al. Salt intakes around the world: implications for public health. Int J Epidemiol 2009; 38: 791-813